glp-1 obesity drug supply news today Agonists Weight Loss Drugs Market Report, 2025-2030 Weight loss with GLP-1 medicines

One recent propensity-matched study even observed a slightly lower lifetime pancreatitis risk in GLP-1RA users (0.3 % vs 0.4 %), possibly reflecting overall better diabetes control [35]

Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial

Developed by Novo Nordisk, WEGOVY (semaglutide) is a GLP-1 receptor agonist designed to support sustainable weight loss when paired with a balanced diet and regular physical activity

Clinically, GLP-1RAs could lead to an improvement in cognitive function, which is often found to be impaired across several conditions such as psychosis 240 and mood disorders 241 , eventually leading to an overall benefit as observed in some of the included studies (Tables 4 and 5)

In one study, liraglutide and semaglutide were reported to mitigate the development of plaque lesions by changing the inflammatory pathway in a mouse model of AS (124)

For people without severe metabolic disease, this often comes down to personal preference